Court may expand 340B drug discount program as CMS preps $9B in payments to 1,700 hospitalsnews2023-11-06T20:15:49+00:00November 6th, 2023|Endpoints News|
HHS says Stelara may be deselected from Medicare negotiations, depending on biosimilar launchnews2023-11-06T19:59:00+00:00November 6th, 2023|Endpoints News|
Kodiak restarts development of Eylea competitor after positive data in diabetic blindnessnews2023-11-06T19:01:31+00:00November 6th, 2023|Endpoints News|
MoonLake’s stock falls more than 20% despite sonelokimab’s mid-stage success in psoriatic arthritisnews2023-11-06T16:38:37+00:00November 6th, 2023|Endpoints News|
Zentalis shakes up PhIII plans in ovarian cancer; Halozyme’s deal with Acumen; Korro’s $117M private placementnews2023-11-06T16:31:29+00:00November 6th, 2023|Endpoints News|
CARGO Therapeutics eyes one of 2023’s largest IPOs in a dull year for listingsnews2023-11-06T16:17:22+00:00November 6th, 2023|Endpoints News|
Cellares to produce Cabaletta’s autoimmune CAR-T candidate news2023-11-06T15:55:12+00:00November 6th, 2023|Endpoints News|
The Endpoints Slack interview: Roivant CEO Matt Gline on pharma moneyball, Vivek, and the $7B Roche dealnews2023-11-06T15:32:06+00:00November 6th, 2023|Endpoints News|
BioNTech pays $55M upfront to partner with Biotheus on PD-L1/VEGF bispecificnews2023-11-06T12:40:50+00:00November 6th, 2023|Endpoints News|
RAPT Therapeutics says adding its CCR4 antagonist to Keytruda boosted response in PhIInews2023-11-06T12:23:13+00:00November 6th, 2023|Endpoints News|
